Navigation Links
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
Date:8/29/2014

previous glioblastoma clinical trials conducted by the National Cancer Institutes in the United States. The Company believes that such higher doses may enhance the potential of VAL-083 to impact a patent's tumor and improve patient outcomes. Ultimately, DelMar believes advancing to higher doses will increase the chance of success in achieving the longer-term goal to commercialize VAL-083 as a new chemotherapy for glioblastoma patients who have failed, or are unlikely to respond, to currently available treatments.
  • DelMar presented new non-clinical research supporting the potential utility of VAL-083 in the treatment of non-small cell lung cancer at AACR in April.
  • DelMar received an additional CDN $194,000 nonrefundable funding contribution from that National Research Council of Canada (NRC). Four non-dilutive funding contributions to date from NRC total CDN $327,000 and will be used to support continued non-clinical research aimed at providing competitive differentiation for VAL-083 as a new medicine in the treatment of glioblastoma and other cancers, including non-small cell lung cancer.
  • DelMar received gross proceeds of $2,373,937 from the exercise of warrants at $0.65 per warrant that closed on June 6 and an additional $495,448 in gross proceeds from exercise of these warrants under the tender offer which closed on August 8. The exercise of warrants through a private transaction with certain warrant holders and subsequent tender offer has provided the Company with additional non-dilutive capital, which the Company believes will be sufficient to fund current operations through at least the end of December 2015. 
  • Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals stated, "We are pleased with the overall progress made during the past year in research and development activities. The warrant tender offer and change in our fiscal year end are part of our ove
    '/>"/>

    SOURCE DelMar Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
    2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
    3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
    4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
    5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
    6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
    7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
    8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
    9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
    10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
    11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... , March 5, 2015 Bayer HealthCare ... to the Conquer Cancer Foundation of the American Society ... edge health information technology platform designed to unlock vast ... with cancer.  "Bayer is proud to ... efforts to leverage Big Data to help people whose ...
    (Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
    (Date:3/5/2015)...  Medical Diagnostic Laboratories, L.L.C., (MDL), a CLIA-certified, ... automated DNA-based molecular analyses, announces that it is ... utilizes cutting edge technology, including next- generation DNA ... women are diagnosed with cervical cancer in ... Papillomaviruses (HPV) are a group of more than ...
    Breaking Medicine Technology:Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
    ... Galien USA committee, responsible for awarding the most prestigious ... 2010 winner of the Pro Bono Humanum Award for ... award, recognizing exemplary and innovative efforts to improve the ... with the Clinton Health Access Initiative (CHAI) for their ...
    ... more information, please go to: http://monistat.presslift.com/yeastinfections . ... from the uncomfortable symptoms of a yeast infection.  In ... experience their first yeast infection before age 25. (1) ... young women ages 18-24 (2), who are new to ...
    Cached Medicine Technology:2010 Prix Galien USA Pro Bono Humanum Award to be Presented to UNITAID for Work In Global HIV/AIDS Effort 2Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections 2Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections 3Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections 4
    (Date:3/5/2015)... 2015 A Bakersfield, Calif. state court jury ... trial awarding the plaintiff Coleen M. Perry a total of ... a TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, Inc., ... , a partner at Wagstaff & Cartmell in ... plaintiff, along with Rich Freese and Tim Goss of ...
    (Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... to move forward in a Pennsylvania mass tort ... Common Pleas, where a jury has begun hearing ... allegations that the atypical antipsychotic medication can cause ... documents, the case in question was filed on ...
    (Date:3/5/2015)... 05, 2015 Central Nebraska Imaging (CNI) ... including the brand’s new logo and optimized website. ... practice’s modern approach to expert diagnostic imaging, centered on ... be built to be a resource for Nebraska patients ... automated forms, communication and referral functionality, video content and ...
    (Date:3/5/2015)... HomeCEUConnection.com is proud to ... savings on their nutrition CEUs. To raise ... nutrition, HomeCEUConnection.com is offering 10% off selected ... NUTRITION2015 . , High Quality Continuing ... provides high-quality continuing education courses for Physical ...
    (Date:3/5/2015)... 2015 On March 2, 2015, NBC ... on the Rise, Plastic Surgeons Say,” that comments on ... for Aesthetic Plastic Surgery and the American ... a year-over-year doubling of surgical butt augmentations performed in ... the article, this increase can be attributed to the ...
    Breaking Medicine News(10 mins):Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2
    ... reverse the health threats, experts say , , THURSDAY, Sept. 20 ... to control their weight by watching their cholesterol by cutting ... total calories and physical activity. And guess what happened to ... an end run around the issue of health maintenance," said ...
    ... scientific researchers: SNM invites you to present your ... molecular imaging techniques and agents -- at the ... New Orleans, La. SNM, the worlds largest society ... showcase these studies in a new scientific investigation ...
    ... 20, 2007 Defects on cell-surface sugars may promote ... the central nervous system of multiple sclerosis patients, according ... also suggest that a dietary supplement similar to glucosamine ... these defects and to treat both the short-term and ...
    ... is challenging conventional thinking on how the cholesterol-reducing drugs ... investigate her findings. , Dr Sarah Calaghan from the ... from Heart Research UK to progress her preliminary evidence ... , For a long time the cardiovascular ...
    ... RFID-based inventory management solution is installed ... track critical medical supplies., BOXBOROUGH, Mass., Sept. 20 ... highest level of care, UMass Memorial Medical Center,located in ... Massachusetts, has installed WaveMark CIMS(TM), an RFID-based,inventory management solution ...
    ... Makes ,House Call, to New Mexico, Urges Residents to Also Press ... ... Sept. 20 The American,Medical Association (AMA) National House Call campaign ... stop scheduled Medicare,cuts. Unless Congress intervenes, Medicare will slash physician payments ...
    Cached Medicine News:Health News:Childhood Obesity Epidemic a Long-Term Challenge 2Health News:Childhood Obesity Epidemic a Long-Term Challenge 3Health News:SNM seeks novel approaches to molecular imaging to showcase at annual meeting 2Health News:Cell-surface sugar defects may trigger nerve damage in multiple sclerosis patients 2Health News:Research to shed new light on how statins benefit heart patients 2Health News:WaveMark, Inc. is Chosen by UMass Memorial Medical Center 2Health News:AMA Urges Congress to Stop Medicare Cuts 2
    Inquire...
    ... an infinity projection, in shorter exam lanes, where ... properly achieved. Thirty individual charts are available. Charts ... linked to the CV-3000 Vision Testing System, using ... done on either a single letter, horizontal line ...
    ... The new FDA-Approved BV-1000 ... automated subjective refraction system. With ... a new generation of refracting ... an objective simultaneous binocular auto-refractor, ...
    Inquire...
    Medicine Products: